What is Kisspeptin-10?
Kisspeptin-10 is a short active kisspeptin sequence studied in reproductive-hormone regulation. Hormonal responses are a starting point for fertility research.
Biological role or research focus
Reproductive hormone signaling.
A short-term hormone response is different from a demonstrated fertility or sexual-function outcome.
Role reference: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗
Names you may encounter
kisspeptin · kisspeptin 10
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Reproductive signaling peptide
- Main research area
- GnRH and LH physiology
- Evidence featured
- Small human physiology study
- Source check
- October 4, 2026
Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗
Quick answers
- Is Kisspeptin-10 FDA approved?
- No. No FDA-approved drug contains Kisspeptin-10. FDA lists it in 503A category 2, substances that may present significant safety risks in compounding. Source ↗
- Is Kisspeptin-10 safe?
- Kisspeptin-10 is an unapproved reproductive-hormone peptide. Only short studies in small groups of healthy men exist, and FDA lists it as a possible significant safety risk in compounding. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Kisspeptin-10 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| LH secretion experiment (2011) | Small human physiology study | Healthy men in small bolus and infusion experiments. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Small human physiology study · 2011
LH secretion experiment
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.
- Population / model
- Healthy men in small bolus and infusion experiments.
- Study design
- Hormone sampling after kisspeptin-10; pulse analysis during infusions.
- Main finding
- LH increased, and infusion changed LH pulse frequency and size. Testosterone also increased in the prolonged-infusion experiment.
- Limits & context
- These are reproductive-hormone endpoints, not pregnancy, live-birth, or sexual-function outcomes. Findings for kisspeptin-10 should not be conflated with trials of kisspeptin-54.
Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
29 registered studies name Kisspeptin-10 as an intervention; 5 are recruiting or under way, 0 have not started recruiting yet, 19 completed and 5 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism NCT04648969 · Stephanie B. Seminara, MD | Completed | Phase 2 | 2019-05-03 | 18 |
| Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea NCT07224438 · Stephanie B. Seminara, MD | Recruiting | Phase 2 | 2025-12-09 | 20 |
| Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease NCT07224490 · Stephanie B. Seminara, MD | Recruiting | Phase 1 | 2026-03-10 | 40 |
| Kisspeptin Administration Subcutaneously to Patients With IHH NCT05896293 · Stephanie B. Seminara, MD | Recruiting | Phase 2 | 2023-02-03 | 36 |
| Functional Proteins in Polycystic Ovary Syndrome NCT06793098 · Jagiellonian University | Recruiting | 2025-01-20 | 100 | |
| Recall by Genotype: Neuropeptide Stimulation NCT05901467 · Stephanie B. Seminara, MD | Terminated | Phase 1 | 2023-10-20 | 16 |
| Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test NCT04958109 · Massachusetts General Hospital | Completed | Phase 1 | 2021-10-28 | 16 |
| Dampening the Reproductive Axis With Continuous Kisspeptin NCT05971849 · Stephanie B. Seminara, MD | Completed | Phase 1 | 2023-10-06 | 8 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 29 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry. ↗
Biomedical chromatography : BMC · 2024 Sep · English Abstract, Journal Article
Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. ↗
Nature communications · 2024 Feb 12 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Author Correction: Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. ↗
Nature communications · 2024 Dec 19 · Published Erratum
Read available full text ↗
Kisspeptin-10 increases collagen content in the myocardium by focal adhesion kinase activity. ↗
Scientific reports · 2023 Nov 15 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Related records in our PubMed snapshot
Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche. ↗
Clinica chimica acta; international journal of clinical chemistry · Issue date 2027 Jan 1 · Not appraised
The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54. ↗
Molecular and cellular endocrinology · Issue date 2026 Oct · Not appraised
Kisspeptin-10 Alleviates Obesity-induced Testicular Oxidative Stress and Mitochondrial Dysfunction via Modulation of Mitophagy and Autophagy Signaling. ↗
Reproductive sciences (Thousand Oaks, Calif.) · Issue date 2026 Sep 28 · Not appraised
Risks & interactions
Kisspeptin-10 is an unapproved reproductive-hormone peptide. Only short studies in small groups of healthy men exist, and FDA lists it as a possible significant safety risk in compounding.
Human studies are small and short, measuring hormone responses over hours to under two weeks. They do not establish reproductive, pregnancy or long-term endocrine safety, and FDA has only limited safety information.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- FDA: possible immune reactions (immunogenicity) and impurity problems; too little data to know whether it causes harm
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · Kisspeptin-10 stimulates LH in men (2011) ↗ · Chronic kisspeptin-10 in healthy men (2026) ↗
Safety evidence & remaining uncertainty
FDA describes limited safety information. Brief exposure in a small group cannot establish reproductive, pregnancy, or long-term endocrine safety.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 2 (FDA flagged significant safety risks)
Listed in 503A category 2 (significant safety risks) since September 29, 2023, citing immunogenicity risk, peptide-impurity complexity and limited safety data. FDA would consider action against compounders using it. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named ("kisspeptin and its agonist analogues"); prohibited in males. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
These physiology findings help explain the reproductive axis. They do not establish successful fertility treatment or sexual-function improvement from a commercial preparation.
Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
Kisspeptin signaling stimulates GnRH-related pathways and downstream gonadotropin release. The selected human study examined LH pulses and testosterone.
Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- A short-term hormone response is different from a demonstrated fertility or sexual-function outcome.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Are kisspeptin-10 and kisspeptin-54 interchangeable study names?
No. They are different peptide lengths, and the exact intervention should be checked.
Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗
Does a higher LH value demonstrate fertility improvement?
No. Clinical fertility outcomes such as pregnancy or live birth must be measured separately.
Source: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
